Characterization of Circulating Tumor DNA for Genetic Assessment of solid Tumors

Personalized cancer therapy requires characterization of the current status of an individual's cancer, necessitating invasive tumor tissue biopsies at diagnosis, during treatment and at progression. Serial acquisition of solid tumor biopsies during treatment to characterize mutations related to...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2015-07, Vol.98 (1), p.16-18
Main Authors: Dorner, AJ, Badola, S, Niu, H
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
DNA - blood
DNA - genetics
Humans
Mutation
Neoplasms - genetics
Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Personalized cancer therapy requires characterization of the current status of an individual's cancer, necessitating invasive tumor tissue biopsies at diagnosis, during treatment and at progression. Serial acquisition of solid tumor biopsies during treatment to characterize mutations related to acquired resistance may not be medically feasible. Circulating tumor DNA (ctDNA) in plasma offers a possible noninvasive “real time” tool for tumor characterization, providing accessible genetic biomarkers for cancer diagnosis, prognosis, and response to therapy.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.130